Last reviewed · How we verify
escitalopram oxalate antidepressant
At a glance
| Generic name | escitalopram oxalate antidepressant |
|---|---|
| Sponsor | Weill Medical College of Cornell University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder (NA)
- Treatment of Psoriasis With Depression and/or Anxiety With Methotrexate vs Combined Methotrexate and Antidepressant (PHASE4)
- Escitalopram in Asthma Patients With Frequent Exacerbation (PHASE2)
- Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole (NA)
- Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure (PHASE3)
- Treating Negative Affect in Low Back Pain Patients (PHASE2, PHASE3)
- Neurobiological and Genomic Predictors of Relapse in Depression
- Multiple Ascending Dose Phase 1 Study of ALA-3000 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: